Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

virbac s.a. - leptospira interrogans serogroup icterohaemorrhagiae (inactivated) 4250 elisa u - 6910 elisa u; leptospira interrogans serogroup canicola (inactivated) 4350 elisa u - 7330 elisa u - suspension for injection - leptospira interrogans canicola; leptospira interrogans icterohaemorrhagiae - leptospira - dog

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

virbac s.a. - leptospira interrogans serogroup icterohaemorrhagiae (inactivated) ; leptospira interrogans serogroup canicola (inactivated) - solution for injection - leptospira interrogans icterohaemorrhagiae; leptospira interrogans canicola - leptospira - dog

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intervet international b.v. - leptospira interrogans serogroup canicola (inactivated) >= 957 u/ml; leptospira interrogans serogroup icterohaemorrhagiae (inactivated) >= 957 u/ml - suspension for injection - leptospira interrogans canicola; leptospira interrogans icterohaemorrhagiae - leptospira - dog

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium - leptospira interrogans serogroup icterohaemorrhagiae (inactivated) 40 u/dose; leptospira interrogans serogroup canicola (inactivated) 40 u/dose - solution for injection - leptospira interrogans canicola; leptospira interrogans icterohaemorrhagiae - leptospira - dog

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

csl limited - leptospira interrogans serovar pomona | leptospira interrogans serovar tarassovi - immunotherapy - cattle | pigs | beef | boar | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | gilt | hei - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus

New Zealand - English - Ministry for Primary Industries

schering-plough animal health limited - clostridium perfringens type d toxoid; clostridium tetani toxoid; clostridium novyi type b toxoid/cells; clostridium septicum toxoid; leptospira interrogans serovar pomona; leptospira borgpetersenii serovar hardjo; clostridium chauvoei toxoid/cells - clostridium perfringens type d toxoid 0 vaccine; clostridium tetani toxoid 0 vaccine; clostridium novyi type b toxoid/cells 0 vaccine; clostridium septicum toxoid 0 vaccine; leptospira interrogans serovar pomona 0 vaccine; leptospira borgpetersenii serovar hardjo 0 vaccine; clostridium chauvoei toxoid/cells 0 vaccine - vaccine

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - canine distemper virus, strain cdv bio 11/a, canine adenovirus type 2, strain cav-2 bio 13, canine parvovirus type 2b, strain cpv-2b bio 12/b, canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (all live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090, l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091... - live canine distemper virus + live canine adenovirus + live canine parainfluenza virus + live canine parvovirus + inactivated leptospira, immunologicals for canidae - dogs - active immunisation of dogs from 6 weeks of age:to prevent mortality and clinical signs caused by canine distemper virus,to prevent mortality and clinical signs caused by canine adenovirus type 1,to prevent clinical signs and reduce viral excretion caused by canine adenovirus type 2,to prevent clinical signs, leucopoenia and viral excretion caused by canine parvovirus,to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus,to prevent clinical signs, infection and urinary excretion caused by l. interrogans serogroup australis serovar bratislava,to prevent clinical signs and urinary excretion and reduce infection caused by l. interrogans serogroup canicola serovar canicola and l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae and to prevent clinical signs and reduce infection and urinary excretion caused by l. interrogans serogroup grippotyphosa serovar grippotyphosa.

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa. - canine parainfluenza type 2 virus, strain cpiv-2 bio 15 (live attenuated), leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090 and l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091 (all inactivated) - immunologicals for canidae, live viral and inactivated bacterial vaccines - dogs - active immunisation of dogs from six weeks of age. - to prevent clinical signs and reduce viral excretion caused by canine parainfluenza virus, - to prevent clinical signs, infection and urinary excretion caused by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. onset of immunity: immunity has been demonstrated from 3 weeks after completion of the primary course for cpiv and from 4 weeks after completion of the primary course for leptospira components. duration of immunity: at least one year following the primary vaccination course for all components of versican plus pi/l4.

European Union - English - EMA (European Medicines Agency)

zoetis belgium s.a. - leptospira interrogans serogroup australis serovar bratislava, strain mslb 1088, l. interrogans serogroup icterohaemorrhagiae serovar icterohaemorrhagiae, strain mslb 1089, l. interrogans serogroup canicola serovar canicola, strain mslb 1090, l. kirschneri serogroup grippotyphosa serovar grippotyphosa, strain mslb 1091 (all inactivated) - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia), immunologicals for canidae - dogs - active immunisation of dogs from six weeks of age to prevent clinical signs, infection and urinary excretion caused by leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae. onset of immunity: immunity has been demonstrated from 4 weeks after completion of the primary course. duration of immunity: at least one year following the primary vaccination course.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - leptospirosis - dog - leptospira icterohaemorrhagiae; canine adeno virus type 2; canine coronavirus vaccine - antigen; canine distemper virus strain onderstepoort; canine parvo virus - misc. vaccines or anti sera - leptospirosis - dog - leptospira icterohaemorrhagiae vaccine active 0.0 u; canine adeno virus type 2 vaccine-viral active 0.0 u; canine coronavirus vaccine - antigen vaccine-viral active 0.0 u; canine distemper virus strain onderstepoort vaccine-viral active 0.0 u; canine parvo virus vaccine-viral active 0.0 u - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus